MedTrace Logo

Study of ORGN001 (Formerly ALXN1101) in Neonates, Infants and Children With Molybdenum Cofactor Deficiency (MOCD) Type A

NCT02629393 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 5

Last updated 2023-10-17

Study results available
· View outcomes & findings →

Summary

To evaluate the safety and efficacy of ORGN001(formerly ALXN1101) in neonate patients with MoCD Type A

Conditions

  • Molybdenum Cofactor Deficiency, Type A

Interventions

DRUG

ORGN001 (formerly ALXN1101)

Sponsors & Collaborators

  • Origin Biosciences

    lead INDUSTRY

Principal Investigators

  • Liza Squires, M.D. · Origin Biosciences

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
1 Day
Max Age
5 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-05-31
Primary Completion
2022-09-30
Completion
2022-10-31

Countries

  • United States
  • Israel
  • Norway
  • Spain
  • Turkey (Türkiye)
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02629393 on ClinicalTrials.gov